AKT2 and cancer: Since HER-2 is not expressed in TNBC diagnosis, the production of nanobodies for the diagnosis and treatment of cancer cells should be performed against other antigens expressed in TNBC such as TNF-α, EGFR, CD3, CTLA-4, STAT3, AKT2, GTP-binding protein Rho, CapG, fibronectin, and CA-IX.